UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~July 221, 2026

_______________________________

Compass Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 57.0301. ~~Amendments~~Regulation toFD ~~Articles of Incorporation or Bylaws; Change in Fiscal Year~~Disclosure.

On ~~June~~July 221, 2026, ~~the Board of Directors (the “Board”) of~~ Compass Therapeutics, Inc. ~~(the~~updated ~~“Company”)~~its ~~approved~~corporate ~~the~~presentation ~~adoption~~to ofreflect ~~the Second Amended and Restated Bylaws of the Company, effective as of June~~its ~~22,~~most ~~2026~~recent ~~(the~~corporate ~~“New Bylaws”)~~updates, ~~which~~including ~~amend~~data ~~and~~from ~~restate~~ the ~~Amended~~COMPANION-002 ~~and~~clinical ~~Restated~~study. ~~Bylaws~~A copy of the ~~Company,~~corporate ~~dated~~presentation asis ~~of July~~furnished ~~17,~~as ~~2020~~Exhibit ~~(the “Existing Bylaws”), in their entirety~~99.1 ~~The New Bylaws amended the Existing Bylaws~~ to ~~establish~~this ~~exclusive~~Current ~~jurisdiction in~~Report ~~the~~on ~~United~~Form ~~States~~8-K ~~District Courts for the District of Delaware~~ and ~~District~~is ofincorporated ~~Massachusetts~~herein ~~for~~by ~~resolving any action asserting a claim arising under Securities Act of 1933, as amended~~reference.

The ~~foregoing~~information ~~description~~contained ofin ~~the~~this ~~New~~Item ~~Bylaws~~7.01 ~~does~~(including ~~not~~Exhibit ~~purport~~99.1) tois bebeing ~~complete~~furnished and ~~is qualified~~ inshall ~~its~~not ~~entirety~~be bydeemed ~~reference~~“filed” tofor ~~the~~purposes ~~full~~of ~~text~~Section 18 of the ~~New~~Exchange ~~Bylaws~~Act, ~~which~~or isotherwise ~~filed~~subject asto ~~Exhibit~~the ~~3.1~~liabilities toof ~~this~~that section ~~Current~~and ~~Report~~shall onnot ~~Form~~be ~~8-K~~deemed ~~and~~incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall isbe ~~incorporated~~expressly ~~herein~~set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		~~Description~~Exhibit
3.1		Second Amended and Restated Bylaws
99.1		Corporate presentation of Compass Therapeutics, Inc. dated July 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.
Date: June 22, 2026	By:	/s/ Neil Lerner
Date: July 1, 2026	By:	/s/ Neil Lerner
		Neil Lerner
		Chief Accounting Officer

Filing Compare · Compass Therapeutics, Inc.